Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. - Wikidata - awgldk - TriplyDB

Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.

Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.

http://www.wikidata.org/entity/Q42625439

about

Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2 [Nobel price for vaccination against cervical cancer: current data and guidelines].Genotype distribution of human papillomavirus (HPV) and co-infections in cervical cytologic specimens from two outpatient gynecological clinics in a region of southeast Spain Multiplexed serologic assay for nine anogenital human papillomavirus types.Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.Characterization and enzyme-conjugation of a specific anti-L1 nanobody.Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.HPV - immune response to infection and vaccination Human papilloma virus vaccines: Current scenario Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2 Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera.Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®)Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines.Vaccination against HPV-Associated Neoplasias: Recommendations from the Current S3 Guideline of the HPV Management Forum of the Paul-Ehrlich Society - AWMF Guidelines, Registry No. 082-002 (short version), valid until Dec. 31st, 2018 Human papillomavirus vaccination in HIV-infected women: need for increased coverage.Human papillomaviruses as therapeutic targets in human cancer.Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia.An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention Dermatologic manifestations of HPV in HIV-infected individuals.Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58 Virus-like particles in vaccine development.Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.Human papillomavirus vaccine: widening the scope for cancer prevention.Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.

P2860

Q28246307-FA829C75-8F5A-485E-989C-34B38F3DA6DE Q28280059-4F17BFDD-800B-4831-B458-7EFC2BFC17C8 Q28741364-846303E4-3E92-41A4-BC33-E840E0E07071 Q33433442-5F92BA30-51EB-476B-A9A2-6D66C596E78C Q33491832-47AADA3A-EA71-493D-8DD6-D1B53147C441 Q33825698-7E69B916-F0D7-4FEB-A4D0-329D11FEADE7 Q34054427-AF97404B-817C-4389-B04D-5335887745F8 Q34256293-78C692C7-6024-45FE-B96F-69D8C99CC386 Q34410377-C67B05A1-A28E-42AE-A3A0-4A80720C572E Q34492140-0E192E30-DB66-44A1-8FF5-E4BC0774F47A Q34612818-18AC5EF4-6AEB-47DC-B165-6ED37CF9C36A Q34639978-9DC5606A-47D5-4939-9514-A5A6753FF842 Q34708325-6AE5BE11-D550-4ED8-951E-3A0195CE6C72 Q35088658-F43C568F-55D8-44BA-98F4-00A33C5FD0CA Q35180148-1D73C8A6-75A5-4B82-A16E-D28074821921 Q35366075-288ADE38-1D51-4FCE-84B2-27C7BAEE293A Q35744303-B88E11E0-55CB-48D1-9DC6-256660522426 Q35818648-35D2D581-56C2-4394-AD92-AAC1AFA2BA74 Q35918838-027A5B51-2F3C-48DD-BA79-940867A38651 Q35985515-BBBCF590-126F-4225-8E11-6E20A2EA39BF Q36305499-723E8A5E-01D2-47E4-A77F-1F0F95A0660F Q36480943-DC48F0FE-48C6-4B0E-9E4C-A0ACA1E458E8 Q36486823-AA8AAA14-21A7-44EB-B030-DD6D05DA6333 Q36736614-6394B5C5-E2DB-4032-923E-757991DA681F Q36743080-B97B2172-FEA2-4DE8-9A18-BD2D5512549C Q36780952-87454D7F-17DD-46EE-8FF9-A31A3E921FEB Q36910331-2BA9E937-252E-422B-A2E8-55B0D53651BF Q36933073-0550C4D3-121B-49C9-A6DB-F02C8C6B9C45 Q37073522-87009C35-33B6-4DBC-81CE-7990BEBB50CB Q37162220-C6942E74-430F-4084-A0B2-9D72873DE875 Q37274559-0BE26371-45FF-48BA-A898-6BF0AABC8C75 Q37546221-C994E271-D6BD-4A94-9A95-97BD27B6D204 Q37671423-9B56D9BC-FD6F-4BEF-8EC8-9CD9D4C6D153 Q37683122-DFB198E8-7AAA-4BFD-9449-03794287D25A Q37712837-B849803E-2EA1-47AA-99C1-9DEADF2858E8 Q37798008-A8E6C608-C972-48FE-81BD-F3A34354FFD0 Q37818140-8257033A-A4FE-41F6-8984-5B9C29EF480F Q37848402-40602620-4025-428F-84BF-032FDB9238A5 Q37861634-C4AE0CFA-F34E-46AE-94A9-2FA1E0C73E4E Q37937705-60CC6339-A741-412E-8D5C-F8DE5142F6CF

P2860

Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.

http://www.wikidata.org/entity/Q42625439

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.

@en

Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.

@nl

type

label

Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.

@en

Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.

@nl

prefLabel

Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.

@en

Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.

@nl

P1433

Q42625439-5A157EC2-C6E9-445F-8F29-28C74D2207F9

P1476

Q42625439-EB93B42D-74D5-40C6-B351-CE903CBE8313

P2093

Q42625439-07C257C9-6FD4-4578-BC44-DF7E19EED44E

Q42625439-54989F95-0833-494D-AF1D-BAAA5B6FB34B

Q42625439-7B7644C6-F5B9-43F6-B031-A37F16B59D93

Q42625439-87DE4F9C-F471-4D41-9FCE-4CFE405CCDFF

Q42625439-90669E1E-A60D-41BA-A4B4-D1832966886A

Q42625439-AD3A32EA-521F-442B-AFC5-6402EED6DC00

Q42625439-C7615331-6C4C-45AF-80EE-EDF09072921E

Q42625439-F5DB14FA-8ACC-4609-B019-94DA6DE179CA

Q42625439-F60821D8-95AB-4A63-95C7-87604C999B41

P304

Q42625439-90DC718B-76F3-4FF5-96A5-E558B0847408

P31

Q42625439-A8CDB01B-F54A-45A3-8926-CF7CA62A3126

P356

Q42625439-ECD2692A-8CC5-475C-8FB4-0F283CD64C69

P433

Q42625439-E318E94E-11B9-439D-92B3-FEA173433B21

P478

Q42625439-01AABCB0-E367-4461-8098-38B91B0E14A6

P577

Q42625439-AB87E5CC-99DF-4E5C-978D-A5FA34841C70

P5875

Q42625439-EDCE3E66-95D8-499C-87CE-040A775FED71

P698

Q42625439-3C82AC42-1E63-4CB2-8D66-17AA05D2708F

P921

Q42625439-2638667B-CFFB-42A8-A0F3-C9B0EF2B1D62

Q42625439-DD4C0E7A-147B-41BF-97B3-445AB2EA9D27

P356

P1433

P1476

Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.

@en

P2093

Darron R Brown

http://www.w3.org/2001/XMLSchema#string

Eliav Barr

http://www.w3.org/2001/XMLSchema#string

Janine T Bryan

http://www.w3.org/2001/XMLSchema#string

Judith F Smith

http://www.w3.org/2001/XMLSchema#string

Mark T Esser

http://www.w3.org/2001/XMLSchema#string

Martha Brown

http://www.w3.org/2001/XMLSchema#string

Michelle Brownlow

http://www.w3.org/2001/XMLSchema#string

Rose Kowalski

http://www.w3.org/2001/XMLSchema#string

Wanda Ruiz

http://www.w3.org/2001/XMLSchema#string

P304

109-115

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/HV.3.4.4058

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6227192

http://www.w3.org/2001/XMLSchema#string

P698

17611417

http://www.w3.org/2001/XMLSchema#string

P921